NCCN awards grant to Threshold hypoxia-targeted prodrug clinical trial
The award has been granted to the Duke Cancer Institute Medicine associate professor Herb Hurwitz. The Duke Cancer Institute plans to commence a Phase 1 clinical trial of
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
PSI-7977 is Pharmasset’s experimental nucleotide polymerase inhibitor and TMC435 is an experimental protease inhibitor of Tibotec. In the trial, the companies expect to investigate the pharmacokinetics, safety and